The Technical Analyst
ETFMG Treatments, Testing [GERM]
Exchange: NYSE
ETFMG Treatments, Testing Price, Forecast, Insider, Ratings, Fundamentals & Signals
-4.20% $17.50
America/New_York / 8 mai 2024 @ 09:30
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 9.04 mill |
| EPS: | 2.57 |
| P/E: | 6.80 |
| Earnings Date: | N/A |
| SharesOutstanding: | 0.517 mill |
| Avg Daily Volume: | 0.0019 mill |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.29x |
| Company: PE 6.80 | sector: PE 23.85 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 0.50x |
| Company: PE 6.80 | industry: PE 13.52 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 17.24 - 17.76 ( +/- 1.48%) |
| ATR Model: 14 days |
Forecast:
11:10 - $17.61
Live Trading Signals (every 1 min)
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 |
| Volume Signals | |
|---|---|
| Price | $17.50 (-4.20% ) |
| Volume | 0.0003 mill |
| Avg. Vol. | 0.0019 mill |
| % of Avg. Vol | 17.88 % |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For GERM
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
GERM
The index tracks the performance of U.S.-listed equity securities or depositary receipts of companies that (i) perform research, development, and commercialization of treatments or vaccines for infectious diseases or (ii) engage in the research, development, manufacturing, and provision of biological tests for patients. The fund invests at least 80% of its total assets in the component securities of the index. The fund is non-diversified.
Latest News
2023-08-29 18:11:07 - ETF Trends
Amplify's Christian Magoon on Purchase of ETFMG's ETFs
In June, the ETF industry learned that issuer ETF Managers Group would be selling its funds to Amplify ETFs. The transaction, once completed, will bring Amplify's total AUM to $8 billion invested across 29 ETFs.
2023-07-21 19:26:39 - ETF Trends
This Week in ETFs: A Summer Slowdown
The week ending Friday, July 21, has been busy for the ETF industry, though launches were muted. A total of seven funds rolled out, which suggests the market could be entering some kind of summer slump.
2023-06-22 15:37:10 - Zacks Investment Research
Biotech ETFs in Focus on Covid Vaccines' Fall Rollout
The FDA advised to Pfizer, Moderna and Novavax to manufacture single-strain jabs targeting the omicron subvariant XBB.1.5 should prove to be a victory for some biotech ETFs.
2023-01-11 18:09:00 - Seeking Alpha
Can Health Care Stocks Outperform Again In 2023?
How a recession could impact health care stocks in 2023. As Covid continues, what it could mean for the health care sector.
2022-10-26 14:18:05 - Zacks Investment Research
Here's Why COVID-Themed ETFs May Come Back Under the Radar
COVID-themed stocks and ETFs were winners in 2020 and some parts of 2021 due to a spike in global coronavirus cases. We may see the same trend again as new COVID variants are 'pretty troublesome.
2022-08-11 08:39:37 - ETF Trends
Biotech ETFs Slip After Novavax Cuts 2022 Guidance
Biotechnology sector-related exchange traded funds retreated with Novavax Inc. (NasdaqGS: NVAX), plunging after the vaccine developer cut its 2022 revenue guidance in half. On Tuesday, the iShares Genomics Immunology and Healthcare ETF (IDNA) fell 4.1%, ETFMG Treatments Testing and Advancements ETF (GERM) dropped 4.3%, SPDR S&P Biotech ETF (XBI) decreased 3.
2022-08-03 18:23:38 - ETF Trends
Moderna Q2 Earnings, Buyback Plans Lift Biotech ETFs
Moderna Inc (NasdaqGS: MRNA) shares surged Wednesday, lifting biotechnology sector-related exchange traded funds, after the pharmaceutical company revealed better-than-expected profit and revenue in its latest quarterly report, along with a share buyback plan. On Wednesday, the Invesco Nasdaq Biotechnology ETF (IBBQ) increased 4.2%, the ETFMG Treatments Testing and Advancements ETF (GERM) advanced 5.
2022-07-08 09:20:07 - Zacks Investment Research
Pharma & Biotech ETFs at One-Month High: Here's Why
2022-03-31 12:25:40 - ETFcom
Vir Jumps 20% On S&P SmallCap 600 News
2022-03-11 15:03:33 - ETFcom
China ETFs Drop On Audit Enforcement
